Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Buy” at Janney Montgomery Scott

Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a neutral rating to a buy rating in a research note issued to investors on Monday, December 4th, Marketbeat Ratings reports. They currently have $47.00 price objective on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on SUPN. Stifel Nicolaus cut shares of Supernus Pharmaceuticals from a buy rating to a hold rating and set a $47.00 target price on the stock. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Cantor Fitzgerald reissued a buy rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a report on Tuesday, September 19th. Piper Jaffray Companies reaffirmed a hold rating and issued a $45.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, September 8th. BidaskClub raised shares of Supernus Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 17th. Finally, SunTrust Banks reaffirmed a buy rating and issued a $61.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Supernus Pharmaceuticals presently has an average rating of Buy and an average price target of $50.00.

Shares of Supernus Pharmaceuticals (SUPN) traded down $0.95 during mid-day trading on Monday, reaching $39.85. 344,899 shares of the company’s stock were exchanged, compared to its average volume of 400,720. Supernus Pharmaceuticals has a 1-year low of $23.10 and a 1-year high of $50.04. The company has a market cap of $2,091.50, a PE ratio of 37.59, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. The business’s revenue was up 41.5% compared to the same quarter last year. research analysts expect that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Neumeier Poma Investment Counsel LLC grew its position in Supernus Pharmaceuticals by 1.6% in the second quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after acquiring an additional 14,430 shares in the last quarter. Teachers Advisors LLC grew its position in Supernus Pharmaceuticals by 6.9% in the second quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock worth $20,087,000 after acquiring an additional 29,939 shares in the last quarter. Royce & Associates LP grew its position in Supernus Pharmaceuticals by 22.3% in the second quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock worth $6,853,000 after acquiring an additional 29,000 shares in the last quarter. Scout Investments Inc. grew its position in Supernus Pharmaceuticals by 2.6% in the second quarter. Scout Investments Inc. now owns 166,675 shares of the specialty pharmaceutical company’s stock worth $7,184,000 after acquiring an additional 4,225 shares in the last quarter. Finally, Royal Bank of Canada grew its position in Supernus Pharmaceuticals by 790.8% in the second quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock worth $11,699,000 after acquiring an additional 240,978 shares in the last quarter. 98.22% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Buy” at Janney Montgomery Scott” was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://weekherald.com/2017/12/30/supernus-pharmaceuticals-supn-lifted-to-buy-at-janney-montgomery-scott.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply